Eleni Karakike, George N Dalekos, Ioannis Koutsodimitropoulos, Maria Saridaki, Chryssa Pourzitaki, Georgios Papathanakos, Antigone Kotsaki, Stamatios Chalvatzis, Vasiliki Dimakopoulou, Nikolaos Vechlidis, Elisabeth Paramythiotou, Christina Avgoustou, Aikaterini Ioakeimidou, Elli Kouriannidi, Apostolos Komnos, Evangelia Neou, Nikoletta Rovina, Eleni Stefanatou, Haralampos Milionis, George Nikolaidis, Antonia Koutsoukou, Georgia Damoraki, George Dimopoulos, Vassileios Zoumpos, Jesper Eugen-Olsen, Karolina Akinosoglou, Nikolaos K Gatselis, Vasilios Koulouras, Eleni Gkeka, Nikolaos Markou, Mihai G Netea, Evangelos J. Giamarellos-Bourboulis
Journal of Innate Immunity 2022;14(3):218-228
DOI: 10.1159/000519090Download pdf 🡇
Funding
This work was supported partly by the Hellenic Institute for the Study of Sepsis and partly by the Horizon 2020 grant RISKinCOVID (Grant No. 961844). The funders had no role in the design, collection, analysis and interpretation of data, writing, and decision to publish.
Keywords: COVID-19; Interleukin 1 receptor antagonist protein; Macrophage activation; Monocytes; Respiratory distress syndrome; Tocilizumab
Related Studies: ESCAPE